Insight /

QUIT GENIUS

QUIT GENIUS - Meet a Vendor

Shortlister hosted Dr. Justin Yang, Quit Genius Medical Director, to provide insights into the importance of destigmatizing addiction. The goal was to help organizations realize that substance use disorders are not moral failing or character flaws but chronic diseases that can be managed with medical treatment.

ADDICTION IS A CHRONIC DISEASE

For employers, addiction is a real business issue, and untreated SUD costs more than untreated mental illness. Like heart disease, hypertension, or diabetes, substance use disorders are also chronic. It’s not, as many people think, a weakness or a moral failing. With 1 in 12 employees struggling with tobacco, alcohol, or opioid addiction, why is this subject still a taboo in the workplace?

ACCELERATION OF SUD THROUGH COVID

Tobacco, Alcohol, and Opioid use, which were already trending upwards, reached their all-time high last year, and the addiction epidemic has yet to peak.

On the other hand 
 
The last two years also saw the century’s most significant shift in healthcare delivery. One that can solve many of the access, quality, and equity challenges we face. Digital health transformed from a convenience to a requirement. 

Virtual care can bend the cost curve in substance addiction as well. 

THE MOST VALIDATED INTEGRATED ADDICTION PROGRAM

Quit Genius is the world’s first virtual clinic for treating substance addictions.  The company was founded by three medical doctors who saw first-hand the toll that substance use disorders had on the lives of their patients. 

Quit Genius addresses the following 3 addictions, most found in the workplace, resulting in the most significant cost to the employer. 

Their treatment programs are clinically based, physician-led, and delivered entirely in a virtual manner.  This approach overcomes the three primary problems related to the traditional addiction treatment delivery model: 

WORKING WITH QUIT GENIUS IS EASY

Log in to access the full Meet A Vendor Presentation!

Not a subscriber? Let’s get in touch!